# Is CPAP the Key to Reduce the Cardiovascular Risk in Patients with OSA?

## TL;DR

This paper explores whether CPAP treatment for sleep apnea can reduce cardiovascular risks in patients.

## Contribution

It reviews recent evidence suggesting CPAP may lower cardiovascular disease risk in OSA patients.

## Key findings

- CPAP therapy lowers blood pressure and reduces sleepiness in OSA patients.
- Consistent CPAP use is linked to fewer serious cardiovascular events.
- Multiple studies show CPAP improves cardiovascular outcomes in OSA patients.

## Abstract

Introduction
 Obstructive sleep apnea (OSA) is a prevalent condition often managed with continuous positive airway pressure (CPAP) treatment. There is an ongoing debate about the link between OSA and cardiovascular disease (CVD), but the existing evidence points toward an association.

Objective
 The present study aims to investigate whether CPAP is an effective strategy to reduce the risk of developing CVD risk among OSA patients.

Methods
 The literature search was conducted in collaboration with Weill Cornell Medical College librarians, and we identified the five most recent papers highlighting the correlation between CPAP treatment for OSA and CVD risk reduction.

Results
 Recent studies highlight the link between OSA and CVD, emphasizing the potential of the CPAP therapy to reduce the risks of developing CVD and the mortality associated with the condition. The analyses by Guo et al., Peker et al., Khan et al., and Wickwire et al., collectively involving thousands of patients across various study designs, including randomized clinical trials and retrospective cohort studies, consistently demonstrate that the CPAP treatment improves cardiovascular outcomes by lowering blood pressure, reducing sleepiness scores, and significantly decreasing the risk of serious CVD events, especially with consistent adherence to therapy.

Conclusion
 Although further studies are needed to confirm these findings among patients with consistent high compliance to the CPAP treatment, it remains reasonable to continue to prescribe CPAP as the first-line therapy for OSA due to its potential cardiovascular benefits and low associated risks.